Moby9h agoneutral
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call SummaryMoby summary of Recursion Pharmaceuticals, Inc.'s Q2 2026 earnings call
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
549last 24h
2530last 7d
483● bullish (7d)
253● bearish (7d)
198publishers
MarketBeat13h agoneutral
Recursion Pharmaceuticals Q2 Earnings Call HighlightsRecursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028. The
Zacks20h agobearish
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue EstimatesRecursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks54d agoneutral
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks61d agoneutral
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool90d agoneutral
Recursion (RXRX) Q1 2026 Earnings TranscriptNajat Khan: Good morning, everyone, and thank you for joining us. First, we're focusing on signal over noise, generating proof and proof points across our both wholly owned programs and our partner programs with the goal to showcase where AI can truly make a difference in creating value.
MarketBeat91d agoneutral
Recursion Pharmaceuticals Q1 Earnings Call HighlightsRecursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership “proof points,” while maintaining what it described as tighter financial discipline. CEO and President
Zacks91d agoneutral
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue EstimatesRecursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +25.42% and -60.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?